Clinical Oncology News | Obinutuzumab Superior to Rituximab in CLL Clinical Oncology News New Orleans—In previously untreated patients with chronic lymphocytic leukemia and comorbidities, the novel CD20-targeted monoclonal antibody obinutuzumab is more active than rituximab, according to results of a Phase III trial that paired both with ... |
